Myriad Genetics, Inc. (NASDAQ: MYGN) has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE